The discounted offering and warrant overhang will pressure the stock near term. Watch for the shareholder vote on authorized share increase (required within 45 days) — failure to pass would block warrant exercises and signal governance risk. The $10M cash runway extends operations but does not change the binary Phase 2 readout risk for onvansertib in RAS-mutated mCRC.
Price Chart
Executive Summary
Cardiff Oncology priced a ~$10M registered direct offering of 8.57M shares + warrants at $1.05/unit (20% discount to last close) with insider participation at $1.455/unit. The dilutive capital raise signals near-term cash needs for a clinical-stage biotech with no approved products, and the warrants add further overhang pending shareholder approval to increase authorized shares.
Key Facts
- Gross proceeds ~$10.05M from 8,571,429 shares + 8,571,429 warrants to institutions at $1.05/unit
- Insider participation: 721,649 shares + 721,649 warrants at $1.455/unit
- Common warrants exercisable at $1.31 ($1.33 for insiders), 5.5-year term, exercisable after 6 months and authorized share increase
- Company must seek stockholder approval to increase authorized shares within 45 days of closing
- H.C. Wainwright placement agent receives 7% cash fee and 465,157 placement agent warrants at $1.3125
- Proceeds for working capital and general corporate purposes
Financial Impact
~$10M gross proceeds with ~16% dilution from shares alone (plus up to 9.3M additional shares from warrants); offering priced at 20% discount to $1.31 last sale
Risk Factors
- Significant dilution from shares and potential full warrant exercise (~9.3M additional shares)
- Shareholder approval needed for authorized share increase — failure could impair warrant value and trigger adverse terms
- Clinical-stage biotech with no approved products; capital raise may signal insufficient pipeline progress
- Warrant overhang may cap upside until exercised or expired
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-305467 |
| Document: crdf-ex4_2.htm | 0001193125-26-305467 |
| Document: crdf-ex4_1.htm | 0001193125-26-305467 |
| Document: crdf-20260714.htm | 0001193125-26-305467 |
| Document: crdf-ex5_1.htm | 0001193125-26-305467 |
| Document: crdf-ex99_1.htm | 0001193125-26-305467 |
| Document: 0001193125-26-305467-index-headers.html | 0001193125-26-305467 |
| Document: 0001193125-26-305467-index.html | 0001193125-26-305467 |
| Document: 0001193125-26-305467.txt | 0001193125-26-305467 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $1.33 $1.17 | ▲ +12.03% | ▲ +10.84% | $0.8000 (+39.85%) |
Sep 14, 2026 6w ago | 8-K | $1.31 $1.37 | ▲ +4.58% | ▲ +4.47% | $0.8000 (−38.93%) |
Aug 11, 2026 10w ago | Press Release | $0.9900 $0.8979 | ▲ +9.30% | ▲ +8.86% | $0.8000 (+19.19%) |
Jul 16, 2026 14w ago | Insider Cluster | $0.8800 $0.8381 | ▼ −4.76% | ▼ −4.07% | $0.8000 (−9.09%) |
Jul 16, 2026 14w ago | 8-K | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8000 (+8.52%) |
Jul 16, 2026 14w ago | 424B5 | $0.8745 $0.8381 | ▲ +4.16% | ▲ +2.49% | $0.8000 (+8.52%) |
Jun 22, 2026 18w ago | Insider Cluster | $1.30 $1.25 | ▼ −3.85% | ▼ −1.78% | $0.8000 (−38.46%) |
Jun 11, 2026 19w ago | Institutional Cluster | $1.59 $1.18 | ▲ +25.79% | ▲ +26.22% | $0.8000 (+49.69%) |
Jun 3, 2026 20w ago | 8-K | $1.40 $1.48 | ▲ +5.71% | ▲ +9.53% | $0.8000 (−42.86%) |
Jun 2, 2026 20w ago | Press Release | $1.51 $1.53 | ▲ +1.32% | ▲ +4.29% | $0.8000 (−47.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers